Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy.
about
Differential Gene Expression Profiling of Dystrophic Dog Muscle after MuStem Cell TransplantationSkeletal muscle homeostasis in duchenne muscular dystrophy: modulating autophagy as a promising therapeutic strategy.One year outcome of boys with Duchenne muscular dystrophy using the Bayley-III scales of infant and toddler development.A comprehensive database of Duchenne and Becker muscular dystrophy patients (0-18 years old) in East ChinaWrist flexion and extension torques measured by highly sensitive dynamometer in healthy subjects from 5 to 80 years.Sulforaphane Attenuates Muscle Inflammation in Dystrophin-deficient mdx Mice via NF-E2-related Factor 2 (Nrf2)-mediated Inhibition of NF-κB Signaling PathwayDp412e: a novel human embryonic dystrophin isoform induced by BMP4 in early differentiated cells.Histologic muscular history in steroid-treated and untreated patients with Duchenne dystrophySatellite Cells in Muscular Dystrophy - Lost in Polarity.Muscle-Derived Proteins as Serum Biomarkers for Monitoring Disease Progression in Three Forms of Muscular Dystrophy.Drug Discovery of Therapies for Duchenne Muscular Dystrophy.Caregiver preferences for emerging duchenne muscular dystrophy treatments: a comparison of best-worst scaling and conjoint analysis.Synthesis of a Morpholino Nucleic Acid (MNA)-Uridine Phosphoramidite, and Exon Skipping Using MNA/2'-O-Methyl Mixmer Antisense Oligonucleotide.Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy.Evaluation of anhydrohexitol nucleic acid, cyclohexenyl nucleic acid and d-altritol nucleic acid-modified 2'-O-methyl RNA mixmer antisense oligonucleotides for exon skipping in vitro.Genetic and pharmacological regulation of the endocannabinoid CB1 receptor in Duchenne muscular dystrophy
P2860
Q27309883-00569200-2439-470F-8805-9B73D1895F87Q33944130-E234B1A7-A7DA-46C5-A7C1-13875EFA9989Q34341005-829C9C65-B1CF-453F-8B82-10A2FF879CF3Q34459245-C005B728-EA66-4F69-BB9C-807FFC0BE8D8Q35067323-9801874E-3501-4932-855B-FFCC0EA94366Q35859481-2FA1CC8D-7D44-4748-A03D-1B23961C8569Q36278519-52DADCFC-48FE-40A5-B9EC-2BB804CD0EB4Q36327073-DC899476-34AA-4BC1-B718-86021E06CD7EQ36948468-71695CF9-3170-4247-9FD8-2026D9325360Q38302852-54AC03E4-C7FB-48EB-8DDF-AE087D01113BQ38480698-13ADAF66-5F01-408B-88C1-A6AD223E292EQ39071862-86A65EAE-681C-42F8-B20A-6C7B15236B3AQ39159171-2C0486D7-B7B9-4B4D-8141-C966A032172CQ48300126-8CA815B6-EE04-4476-A5DE-FF13DAAD7F2EQ48952319-06261B53-EE37-44E7-A5A5-B1FF6F24B025Q59128911-CBDBD86E-1D23-455E-80C9-AB06B2354F0B
P2860
Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy.
@en
type
label
Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy.
@en
prefLabel
Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy.
@en
P2860
P50
P1476
Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy
@en
P2093
Chiara Zanetta
Simona Brajkovic
P2860
P2888
P304
P356
10.1007/S00018-013-1396-Z
P577
2013-06-18T00:00:00Z